CDC Releases 2023 STI Surveillance Report
From HIV.gov… After several years of increases, the data suggest that the STI epidemic may be slowing. We still have much more work to do, but the 2023 data are promising in several aspects: These signs of hope hint at what’s possible when the nation prioritizes – and invests in – STI prevention. The data arrive […]
MMWR Supplement on National HIV Behavioral Surveillance Among Transgender Women—Seven Urban Areas, United States, 2019-2020
From SAGE Public Health Reports… The analyses presented in the MMWR Supplement “National HIV Behavioral Surveillance Among Transgender Women—Seven Urban Areas, 2019-2020” highlight findings from the Centers for Disease Control and Prevention’s National HIV Behavioral Surveillance Among Transgender Women (NHBS-Trans) project conducted during 2019-2020. Each article in the supplement presents findings related to unique aspects of the […]
MMWR: Needs of Older People Living With HIV Unmet
From POZ.com… The needs of older people living with HIV are going unmet, and the United States is unlikely to reach five goals for improving quality of life for those ages 50 and older by 2025, according to a Centers for Disease Control and Prevention (CDC) analysis published in Morbidity and Mortality Weekly Report. Thanks to […]
DoxyPrEP shows major reductions in STIs: studies
From PositivelyAware.com… Troy Grennan, MD, MSc, a clinical associate professor at the University of British Columbia, shared findings of a randomized controlled trial that studied the efficacy, tolerability, and use patterns of doxyPrEP. The trial included 52 men who have sex with men, all living with HIV and having a history of syphilis, in Toronto and Vancouver, Canada. The […]
CDC Publishes New HIV Surveillance Reports
From HIV.gov… The Centers for Disease Control and Prevention (CDC) published three new HIV surveillance reports: Estimated HIV Incidence and Prevalence in the United States, 2018-2022; Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data, United States and 6 Territories and Freely Associated States, 2022; and Diagnoses, Deaths, and Prevalence of HIV […]
Pitt AIDS study hits milestone birthday, turns to questions of aging with HIV
From WESA… This month marks 40 years since the Pitt Men’s Study started enrolling volunteers in what has become one of the longest-running U.S. studies of HIV and AIDS. AIDS is the most severe stage of HIV, which interferes with the immune system’s ability to fight infection and disease. The first cases of AIDS in […]
Factors Associated with PrEP Stigma Among Gay, Bisexual, and Other Men Who Have Sex with Men (gbMSM): A Systematic Review
New research on PubMed… “Gay, bisexual, and other men who have sex with men (gbMSM) are disproportionately affected by HIV. While pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV acquisition, uptake of PrEP among gbMSM is low, which may in part be due to stigma associated with PrEP use.” Find out more on PubMed. […]
A Call to End Stigmatizing Language in HIV Research
From positivelyaware.com… A coalition of HIV activists and about 50 organizations are sending a letter to the National Institute of Allergy and Infectious Disease (NIAID), calling on the agency to require the use of non-stigmatizing language in HIV research. Addressed to NIAID director Jeanne Marrazzo, MD, MPH, who was named to the position last August […]
Latest CDC Surveillance Report shows HIV dropped 17% in the U.S.
From the CDC: A new CDC report shows HIV has declined stedily from 2017 to 2021 in the U.S. Men still account for the majority of cases (81%) and male-to-male sexual contact is still the most previlent means of transmitting the virus. Find out more on the CDC’s website. To find local HIV testing, you […]
Twice-Yearly Sunlenca Works Well for Initial HIV Treatment
From Poz Magazine online… Sunlenca (lenacapavir), a long-acting injectable medication recently approved for treatment-experienced people with multidrug-resistant HIV, also works well for people starting antiretroviral therapy for the first time. Results from the CALIBRATE trial showed that around 90% of study participants who used Sunlenca—either as daily pills or injections every six months—in combination with […]